People · Operator
Named in public records as an officer, director or promoter · active 2015–2024 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Summit Therapeutics Inc. | — | Biotechnology | Series D+ | $569.0M | $2.4B | 2020 |
| Medable Inc. | — | Other Health Care | Series D+ | $501.0M | $5.4B | 2015 |
| Pulse Biosciences, Inc. | — | Biotechnology | Series C | $93.0M | $1.4B | 2021 |
Mahkam Zanganeh at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mahkam Zanganeh on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Duggan | 3 | 3 |
| Kenneth Clark | 2 | 3 |
| Manmeet Soni | 2 | 2 |
| Jeff Huber | 1 | 75 |
| Mostafa Ronaghi | 1 | 8 |
| David Wurzer | 1 | 7 |
| Amy Wang | 1 | 5 |
| Timothy Smith | 1 | 5 |
| Jim Mellon | 1 | 4 |
| Robert Booth | 1 | 4 |
| Raymond Spencer | 1 | 3 |
| David Roblin | 1 | 3 |
| Christopher Marlett | 1 | 3 |
| Darrin Uecker | 1 | 3 |
| Barry Price | 1 | 2 |
| Leopoldo Zambeletti | 1 | 2 |
| Michelle Longmire | 1 | 2 |
| Robert Levande | 1 | 2 |
| Mitchell Levinson | 1 | 2 |
| Glyn Edwards | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.